

# **Supplementary Material**

## **Table of Contents**

Supplementary Methods.....	3
Genes used in next generation panel for targeted sequencing (TS). .....	3
Whole blood sample processing .....	3
Targeted deep sequencing .....	3
Droplet Digital PCR .....	4
Supplementary Table S1. Demographic characteristics, medical conditions, and clinical pathology results of study participants.....	5
Supplementary Table S2. Clinical characteristics of study participants with HIV.....	14
Supplementary Table S3. Characteristics of mutations associated with clonal haematopoiesis.	19
Supplementary Table S4. Identified mutations associated with clonal haematopoiesis .....	21
Supplementary Table S5. Sensitivity analysis of the association between HIV infection and the presence of having $\geq 1$ CH mutation .....	26
Supplementary Table S5.A. Mutations with variant allele fraction>2% only .....	26
Supplementary Table S5.B. Mutations in DNMT3A, TET2 and ASXL1 only .....	28
Supplementary Table S5.C. Men only .....	30
Supplementary Table S5.D. MSM only .....	31
Supplementary Table S6. Univariate analysis of risk factors for having $\geq$ one CH mutation among HIV positive participants (N=220) .....	32

Supplementary Figure S1: Variant allele fraction by duration of HIV, among HIV positive participants <sup>1</sup> .....	37
Supplementary Figure S2. Box plots of the distribution of blood cell characteristics and inflammatory markers.....	38
References.....	40

## Supplementary Methods

### Genes used in next generation panel for targeted sequencing (TS).

GENE						
ASXL1*	DIS3	GNAS	MLL2	PHF6	SF3B1	TP53
BCOR	DNMT3A	IDH1	MPL	PRPF40B	SMC1a	U2AF1
BRAF	DOCK4	IDH2	MYC	PTEN	SMC3	UMODL1
CALR	ETV6	JAK2	NF1	PTPN11	SRSF2	WAC
CBL	EZH2	KDM6A	NPM1	RAD21	STAG2	WT1
CDKN2A	FLT3	KIT	NRAS	RUNX1	STAT3	ZRSR2
CSF1R	GATA1	KRAS	PDGFRA	SETBP1	SUZ12	PPM1D
UX1	GATA2	MLL	PDS5B	SF3A1	TET2	

\* Excluding *ASXL1* c.1934dupG;p.Gly646TrpfsX12.

### Whole blood sample processing

Whole blood from enrolled participants were collected in ethylenediaminetetraacetic acid (EDTA) tubes. DNA from whole blood was extracted using the QIAsymphony DNA Midi Kit (Qiagen, #931255) according to manufacturer's protocols.

### Targeted deep sequencing

Target specific amplification was performed using the Fluidigm Access Array™ system. Following amplification, products were harvested, tagged with sample-specific barcodes, pooled together, and purified using AMPure XP beads. All samples were analysed in duplicate to control for PCR artefacts. The purified libraries were then sequenced using 150 bp read length on the

Illumina MiSeq or NextSeq platform. Sequenced reads were mapped to the human reference genome (version hg19) using BWA-MEM (version 0.7.12) with default parameters. All samples were tested in at least 2 technical replicates. Variant calling was performed using an in-house pipeline<sup>1</sup>. Mutations with at least 300x coverage with a minimum of 30 reads supporting the variant and a mutant allele fraction greater than 1% were retained for further analysis. The median targeted sequencing coverage over variant reads was 3210-fold. Variants that were recurrently observed in more than 1% of the samples (representing likely sequencing and/or PCR artefacts) and those with a high global allele frequency (>1%) in population databases (gnomAD) were flagged and removed from this curated list. In addition, the *ASXL1* c.1934dupG; p.Gly646TrpfsX12 variant was excluded from analysis to eliminate the possibility false positive results given the high susceptibility to PCR artefact within this region. Variants in the curated list were then annotated based on their prognostic or functional relevance<sup>2</sup>. Our analysis did not include paired germline sample to definitively exclude germline variants. To account for this, variants greater than 30% allele frequency were not included in the final curated list unless they had been described in COSMIC.

### **Droplet Digital PCR**

Digital PCR was used to assess for the presence of the IL6R p.Asp358Ala polymorphism. In addition, it was used to validate hotspot mutations in *DNMT3A* Arg882His, Arg882Cys and *JAK2* Val617Phe detected by targeted sequencing. This was performed using the Bio-Rad QX200 Droplet digital PCR system following manufacturer's protocols. Allele-specific PCR assays to specifically detect and quantify the fractional abundance of point mutations and corresponding wild-type alleles were commercially obtained (PrimePCR™ PCR Primers and Assays, BioRad

Laboratories). Each sample was analysed by at least two technical replicates. Data analysis was carried out using the QuantaSoft Software (Bio-Rad).

**Supplementary Table S1. Demographic characteristics, medical conditions, and clinical pathology results of study participants**

	HIV Negative N = 226	HIV Positive N = 220	All Participants N = 446
	n (%)	n (%)	n (%)
<b>Aboriginal or Torres Strait Islander</b>			
Yes	1 (0.4)	2 (0.9)	3 (0.7)
No	204 (90.3)	189 (85.9)	393 (88.1)
Missing	21 (9.3)	29 (13.2)	50 (11.2)
<b>Ancestry</b>			
Australia, New Zealand, Europe, United States of America			
States of America	185 (81.9)	168 (76.4)	353 (79.2)
Other	18 (8.0)	22 (10.0)	40 (9.0)
Missing	23 (10.2)	30 (13.6)	53 (11.9)
<b>Sexual orientation</b>			
Men sexually active with men or both men and women (MSM)			
	189 (83.6)	201 (91.4)	390 (87.4)
Heterosexual men	16 (7.1)	11 (5.0)	27 (6.1)
Heterosexual women	11 (4.9)	4 (1.8)	15 (3.4)
Bisexual women	1 (0.4)	0	1 (0.2)
Missing	9 (4.0)	4 (1.8)	13 (2.9)

---

**Tobacco use**

Number of years smoking cigarettes  
regularly

Never smoked	108 (47.8)	87 (39.6)	195 (43.7)
<30 years	50 (22.1)	45 (20.5)	95 (21.3)
≥30 years	44 (19.5)	56 (25.5)	100 (22.4)
Smoked but missing data on duration	2 (0.9)	3 (1.4)	5 (1.2)
Missing tobacco use history	22 (9.7)	29 (13.2)	51 (11.4)

Number of cigarettes per day

Never smoked	108 (47.8)	87 (39.6)	195 (43.7)
<10/day	23 (10.2)	19 (8.6)	42 (9.4)
≥10/day	71 (31.4)	82 (37.3)	153 (34.3)
Smoked but missing data on quantity	2 (0.9)	3 (1.4)	5 (1.1)
Missing tobacco use history	22 (9.7)	29 (13.2)	51 (11.4)

---

**Alcohol use**

Number of years drank regularly

Never drank	7 (3.1)	10 (4.6)	17 (3.8)
<20 years	32 (14.2)	29 (13.2)	61 (13.7)
≥20 years	161 (7.2)	146 (66.4)	307 (68.8)
Drank but missing data on duration	4 (1.8)	6 (2.7)	10 (2.2)
Missing alcohol use history	22 (9.7)	29 (13.2)	51 (11.4)

Average number of drinks per week

Never drank	7 (3.1)	10 (4.6)	17 (3.8)
≤14	148 (65.5)	162 (73.6)	310 (69.5)
>14	46 (20.4)	17 (7.7)	63 (14.1)
Drank but missing data on quantity	3 (1.3)	2 (0.9)	5 (1.1)
Missing alcohol use history	22 (9.7)	29 (13.2)	51 (11.4)
<b>Socioeconomic factors</b>			
Yearly household income			
<50k	64 (28.3)	100 (45.5)	164 (36.8)
≥50k	118 (52.2)	66 (30.0)	184 (41.3)
Missing	44 (19.5)	54 (24.6)	98 (22.0)
<b>Medical conditions</b>			
Cardiovascular conditions, any	148 (65.5)	141 (64.1)	289 (64.8)
Hypertension	85 (37.6)	86 (39.1)	171 (38.3)
Hyperlipidaemia	92 (40.7)	76 (34.6)	168 (37.7)
Coronary artery disease	19 (8.4)	25 (11.4)	44 (9.9)
Myocardial infarction	13 (5.8)	13 (5.9)	26 (5.8)
Cerebrovascular accident	4 (1.8)	9 (4.1)	13 (2.9)
Congestive heart failure	3 (1.3)	1 (0.5)	4 (0.9)
Other heart disease	22 (9.7)	26 (11.8)	48 (10.8)
Coronary artery disease or myocardial infarction	27 (12.0)	31 (14.1)	58 (13.0)
Coronary artery disease or myocardial infarction or cerebrovascular accident	30 (13.3)	38 (17.3)	68 (15.3)
Malignancies, any	48 (21.2)	60 (27.3)	108 (24.2)

Solid tumors other than skin cancers <sup>1</sup>	20 (8.9)	29 (13.2)	49 (11.0)
Prostate	10 (4.4)	7 (3.2)	17 (3.8)
Kaposi's sarcoma	1 (0.4)	9 (4.1)	10 (2.2)
Anal	2 (0.9)	7 (3.2)	9 (2.0)
Bowel	2 (0.9)	3 (1.4)	5 (1.1)
Lung	2 (0.9)	0	2 (0.5)
Breast	1 (0.4)	0	1 (0.2)
Cervical or ovarian	0	0	0
Other <sup>2</sup>	4 (1.8)	8 (3.6)	12 (2.7)
Skin cancers	33 (14.6)	33 (15.0)	66 (14.8)
Haematologic <sup>3</sup>	1 (0.4)	7 (3.2)	8 (1.8)
<hr/> Liver conditions, any	35 (15.5)	45 (20.5)	80 (17.9)
Liver conditions other than viral hepatitis	9 (4.0)	11 (5.0)	20 (4.5)
<hr/> Diabetes	29 (12.8)	31 (14.1)	60 (13.5)
<hr/> Respiratory conditions, any	40 (17.7)	52 (23.6)	92 (20.6)
Asthma	27 (12.0)	29 (13.2)	56 (12.6)
Community-acquired pneumonia	4 (1.8)	9 (4.1)	13 (2.9)
Other pneumonia	0	7 (3.2)	7 (1.6)
Other lung condition	15 (6.6)	22 (10.0)	37 (8.3)
<hr/> Kidney disease	7 (3.1)	17 (7.7)	24 (5.4)
<hr/> Blood disorders	12 (5.3)	22 (10.0)	34 (7.6)
<hr/> Musculoskeletal, any	66 (29.2)	72 (32.7)	138 (30.9)
Osteoporosis or other bone disease	24 (10.6)	33 (15.0)	57 (12.8)
Hip fracture	0	1 (0.5)	1 (0.2)

	HIV Negative	HIV Positive	All Participants
Vital signs <sup>4</sup>	N = 226	N = 220	N = 446
	Median (IQR)	Median (IQR)	Median (IQR)
BMI	26.4 (23.7-29.1)	25.7 (23.5-28.4)	26.0 (23.6-29.0)
Underweight (BMI<18.5), n (%)	1 (0.4)	2 (0.9)	3 (0.7)

	Normal (BMI 18.5-<25), n (%)	82 (36.3)	86 (39.1)	168 (37.7)
	Overweight (BMI 25-<30), n (%)	93 (41.2)	94 (42.7)	187 (41.9)
	Obese (BMI ≥30), n (%)	49 (21.7)	38 (17.3)	87 (19.5)
	Missing, n (%)	1 (0.4)	0	1 (0.2)
Waist circumference (cm)		99 (92-105)	97 (91-104)	98 (91-105)
Missing, n (%)		38 (16.8)	22 (10.0)	60 (13.5)
Systolic blood pressure (mmHg)		130 (121-140)	130 (120-140)	130 (121-140)
Missing, n (%)		1 (0.4)	0	1 (0.2)
Diastolic blood pressure (mmHG)		78 (72-86)	80 (72-85)	79 (72-85)
Missing, n (%)		1 (0.4)	0	1 (0.2)
	HIV Negative	HIV Positive	All Participants	
Clinical pathology results	N = 226	N = 220	N = 446	
	Median (IQR)	Median (IQR)	Median (IQR)	
Total cholesterol	4.8 (4.2-5.6)	4.7 (4.0-5.5)	4.7 (4.1-5.6)	
Recency of test (days)	83 (0-266)	64 (0-183)	70 (0-244)	
Missing, n (%)	15 (6.6)	1 (0.5)	16 (7.3)	
LDL	2.8 (2.1-3.5)	2.5 (1.9-3.2)	2.6 (2.0-3.4)	
Recency of test (days)	73 (0-264)	76 (4-215)	75 (0-251)	
Missing, n (%)	22 (9.7)	7 (3.2)	29 (13.2)	
HDL	1.3 (1.1-1.7)	1.3 (1.0-1.5)	1.3 (1.1-1.6)	
Recency of test (days)	82 (0-260)	65 (4-191)	70 (0-245)	
Missing, n (%)	22 (9.7)	3 (1.4)	25 (11.4)	
Triglycerides	1.3 (0.9-1.9)	1.5 (1.1-2.4)	1.4 (1.0-2.2)	
Recency of test (days)	72 (0-263)	64 (0-183)	65 (0-242)	

Missing, n (%)	17 (7.5)	1 (0.5)	18 (8.2)
Glucose	5.4 (4.9-5.8)	5.2 (4.8-6.0)	5.3 (4.9-5.9)
Recency of test (days)	89 (0-317)	57 (0-202)	71 (0-253)
Missing, n (%)	14 (6.2)	10 (4.5)	24 (10.9)
Creatinin	83 (74-93)	92 (80-105)	87 (76-99)
Recency of test (days)	40 (0-219)	15 (0-85)	25 (0-126)
Missing, n (%)	5 (2.2)	0	5 (2.3)
ALT	26 (19-34)	28 (20-39)	27 (20-36)
Recency of test (days)	47 (0-244)	18 (0-91)	29 (0-133)
Missing, n (%)	9 (3.9)	0	9 (4.1)
AST	25 (21-30)	26 (22-34)	25 (21-31)
Recency of test (days)	51 (0-245)	36 (0-122)	42 (0-153)
Missing, n (%)	10 (4.4)	21 (9.5)	31 (14.1)

	HIV Negative	HIV Positive	All Participants
<b>Study pathology results<sup>5</sup></b>	<b>N = 226</b>	<b>N = 220</b>	<b>N = 446</b>
	<b>Median (IQR)</b>	<b>Median (IQR)</b>	<b>Median (IQR)</b>

#### Full blood examination

Haemoglobin	146 (136-153)	149 (141-156)	147 (139-155)
Missing, n (%)	1 (0.4)	3 (1.4)	4 (0.9)
White blood cell count	5.7 (4.8-6.6)	6.1 (4.8-7.7)	5.9 (4.8-7.0)
Missing, n (%)	1 (0.4)	3 (1.4)	4 (0.9)
Neutrophil count	3.2 (2.5-4.0)	3.4 (2.6-4.3)	3.3 (2.5-4.2)
Missing, n (%)	1 (0.4)	3 (1.4)	4 (0.9)
Lymphocyte count	1.7 (1.4-2.1)	1.8 (1.5-2.3)	1.8 (2.2-1.4)

Missing, n (%)	1 (0.4)	3 (1.4)	4 (0.9)
Platelets	209 (180-240)	200 (165-239)	204 (175-140)
Missing, n (%)	1 (0.4)	6 (2.7)	7 (1.6)
Mean Corpuscular Volume	92 (89-95)	95.7 (92.0-99.0)	94 (90-97)
Missing, n (%)	1 (0.4)	3 (1.4)	4 (0.9)
Red cell distribution width	13.4 (12.9-13.9)	13.3 (12.9-13.9)	13.4 (12.9-13.9)
Missing, n (%)	1 (0.4)	3 (1.4)	4 (0.9)
<b>Inflammatory markers</b>			
Interleukin 6	1.99 (1.50-2.80)	2.37 (1.82-3.36)	2.15 (1.61-3.03)
Missing, n (%)	1 (0.4)	2 (0.9)	3 (0.7)
hs CRP	1.5 (0.7-3.0)	2.0 (0.9-4.1)	1.7 (0.8-3.7)
Missing, n (%)	8 (3.5)	2 (0.9)	10 (2.2)
Cystatin C	0.93 (0.82-1.07)	0.99 (0.88-1.15)	0.95 (0.86-1.11)
Missing, n (%)	2 (0.9)	1 (0.5)	3 (0.7)
D-dimer			
<0.27 mg/L, n (%)	104 (46.0)	100 (45.5)	204 (45.7)
≥0.27 mg/L, n (%)	120 (53.1)	116 (52.7)	236 (52.9)
Missing, n (%)	2 (0.9)	4 (1.8)	6 (1.4)

<sup>1</sup>Other solid tumor sites include: HIV negative (n=1 for all): kidney, thyroid, sarcoma, tongue; HIV positive (one participant had two cancers): bladder (n=2), facial nerve (n=1), head and neck (n=1), pancreatic (n=1), liposarcoma (n=1), tongue (n=1), testicular (n=1), thyroid (n=1)

<sup>2</sup>Includes Kaposi's sarcoma

<sup>3</sup>Haematologic malignancies and years of first diagnosis: HIV negative (n=1): Non-Hodgkins Lymphoma (2003); HIV positive (n=1 for all): Hodgkins Lymphoma (1990), Hodgkins Lymphoma (2004), Non-Hodgkin's Lymphoma (2004), Hodgkin's Lymphoma (2006), Multiple Myeloma (2008), gastric

lymphoma (2011), Chronic Myeloid Leukemia (2017). One of the eight participants with haematologic malignancies also had a mutation associated with clonal haematopoiesis.

<sup>4</sup>The median time from vital sign measurement to enrolment was 0 days (IQR 0-0 days) overall and when stratified by HIV status

<sup>5</sup>Tested at study enrolment visit

**Supplementary Table S2. Clinical characteristics of study participants with HIV**

Characteristic	N=220
	n (%)
Years since HIV diagnosis*, median (IQR)	24 (15-31)
<10	21 (9.6)
10-19	64 (29.1)
20-29	65 (29.6)
≥30	66 (30.0)
Missing	4 (1.8)
CD4 nadir, median (IQR)	248 (151-383)
<50	18 (8.2)
50-199	57 (25.9)
200-349	76 (34.6)
350-499	38 (17.3)
≥500	28 (12.7)
Missing	3 (1.4)
Current CD4, median (IQR)	649 (464-859)
<200	4 (1.8)
200-349	22 (10.0)
350-499	39 (17.7)
≥500	153 (69.6)
Missing	2 (0.9)
Current HIV VL	

<40	210 (95.5)
40-199	8 (3.6)
≥200	2 (0.9)
Missing	0
<hr/>	
Currently taking ART	
Yes	219 (99.6)
Prior ART	1 (0.5)
Missing	0
<hr/>	
When started ART	
Pre-HAART (before 1996)	40 (18.2)
Early HAART (1996-2005)	88 (40.0)
Modern HAART (since 2006)	83 (37.7)
Missing	9 (4.1)
<hr/>	
Years since starting ART, Median (IQR)	17 (9-21)
<10	53 (24.1)
10-19	77 (35.0)
≥20	81 (36.8)
Missing	9 (4.1)
<hr/>	
<20	130 (59.1)
≥20	81 (36.8)
Missing	9 (4.1)
<hr/>	
Proportion of time since HIV diagnosis that participant was taking ART**	

>75%	108 (49.1)
≤75%	99 (45.0)
Missing	13 (5.9)
<hr/>	
Stavudine and zidovudine exposure	
Stavudine	
Ever took	77 (35.0)
Never took	138 (62.7)
Missing	5 (2.3)
Years took stavudine, median (IQR)	2 (1-5)
Missing n (% of ever took)	24 (28.6)
Zidovudine	
Ever took	91 (41.4)
Never took	124 (56.4)
Missing	5 (2.3)
Years took zidovudine, median (IQR)	3 (1-7)
Missing n (% of ever took)	19 (20.9)
Ever took either stavudine or zidovudine	
Ever took either	115 (52.3)
Never took either	100 (45.5)
Missing	5 (2.3)

Years took either stavudine or zidovudine***,	
median (IQR)	5 (2-8)
Missing n (% of ever took)	26 (22.6)
<hr/>	
Current ART regimen	
Dolutegravir/abacavir/lamivudine	27 (12.3)
Dolutegravir/emtricitabine/tenofovir alafenamide	23 (10.5)
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide	22 (10.0)
Raltegravir/emtricitabine/tenofovir alafenamide	16 (7.3)
Rilpivirine/emtricitabine/tenofovir alafenamide	12 (5.5)
Darunavir/cobicistat/dolutegravir	9 (4.1)
Nevirapine/emtricitabine/tenofovir alafenamide	9 (4.1)
Efavirenz/emtricitabine/tenofovir disoproxil fumarate	7 (3.2)
Dolutegravir/abacavir/lamivudine/maraviroc	7 (3.2)
Nevirapine/abacavir/lamivudine	5 (2.3)
Nevirapine/lamivudine/zidovudine	4 (1.8)
Darunavir/ritonavir/raltegravir	3 (1.4)
Raltegravir/emtricitabine/tenofovir disoproxil fumarate	3 (1.4)
Other ( $\leq$ 2 participants per regimen)	72 (32.7)
Not taking ART	1 (0.5)

\*number of years from year of diagnosis to year of enrolment

\*\*years on ART / years since diagnosis

\*\*\*sum of the years on each individual drug

**Supplementary Table S3. Characteristics of mutations associated with clonal haematopoiesis**

Characteristic	HIV negative	HIV positive	All
	N=51	N=81	N=132
	n (%)	n (%)	n (%)
<b>Variant allele fraction</b>			
Median (IQR)	4.0 (2.4 – 8.4)	4.7 (2.6 – 8.6)	4.6 (2.6 – 8.6)
≤2	8 (15.7)	7 (8.6)	15 (11.4)
>2-≤5	20 (39.2)	37 (45.7)	57 (43.2)
>5-≤10	12 (23.5)	18 (22.2)	30 (22.7)
>10	11 (21.6)	19 (23.5)	30 (22.7)
<b>Genes</b>			
DNMT3A	27 (53.0)	37 (45.7)	64 (48.5)
TET2	11 (21.6)	16 (19.8)	27 (20.5)
ASXL1	2 (3.9)	13 (16.1)	15 (11.4)
TP53	3 (5.9)	4 (4.9)	7 (5.3)
PPM1D	2 (4.0)	3 (3.7)	5 (3.8)
JAK2	1 (2.0)	2 (2.5)	3 (2.3)
SF3B1	2 (4.0)	1 (1.2)	3 (2.3)
U2AF1	1 (2.0)	2 (2.5)	3 (2.3)
EZH2	1 (2.0)	0	1 (0.8)
MPL	0	1 (1.2)	1 (0.8)
SETBP1	0	1 (1.2)	1 (0.8)
STAG2	1 (2.0)	0	1 (0.8)

STAT3	0	1 (1.2)	1 (0.8)
<b>Type of mutation</b>			
Missense	24 (47.1)	29 (35.8)	53 (40.2)
Frameshift	18 (35.3)	28 (34.6)	46 (34.9)
Stop gained	5 (9.8)	16 (19.8)	21 (15.9)
Splice donor	2 (3.9)	4 (4.9)	6 (4.6)
Splice acceptor	1 (2.0)	2 (2.5)	3 (2.3)
Inframe deletion	1 (2.0)	1 (1.2)	2 (1.5)
Inframe insertion	0	1 (1.2)	1 (0.8)
Missense mutations	24 (47.1)	29 (35.8)	53 (40.2)
Truncating <sup>1</sup>	26 (51.0)	50 (61.7)	76 (57.6)
Inframe deletions or insertions	1 (2.0)	2 (2.5)	3 (2.3)
<b>Location of mutation within gene</b>	<b>N=27</b>	<b>N=37</b>	<b>N=64</b>
(DNMT3A only)			
Mtase	16 (59.3)	19 (51.4)	35 (54.7)
PWWP	4 (14.8)	7 (18.9)	11 (17.2)
ADD	5 (18.5)	5 (13.5)	10 (15.6)
Interaction with DNMT1 and			
DNMT3B	2 (7.4)	4 (10.8)	6 (9.4)
Close to MTase	0	2 (5.4)	2 (3.1)

<sup>1</sup>frame shift, stop gained, splice donor and splice acceptor mutations

**Supplementary Table S4. Identified mutations associated with clonal haematopoiesis**

Subject	Gene	hgvsC	hgvsP	consequence	Variant allele frequency
03-001	TP53	NM_000546.5:c.559+1G>A	p.?	splice_donor_variant	2.04
03-001	TP53	NM_000546.5:c.481G>T	NP_000537.3:p.(Ala161Ser)	missense_variant	2.85
03-006	PPM1D	NM_003620.3:c.1434C>A	NP_003611.1:p.(Cys478*)	stop_gained	7.23
03-008	PPM1D	NM_003620.3:c.1442_1449del	NP_003611.1:p.(Ala481Valfs*5)	frameshift_variant	11.75
03-009	DNMT3A	NM_022552.4:c.2478+2T>C	p.?	splice_donor_variant	13.04
03-013	DNMT3A	NM_022552.4:c.1567G>T	NP_072046.2:p.(Glu523*)	stop_gained	2.15
03-013	DNMT3A	NM_022552.4:c.654dup	NP_072046.2:p.(Lys219Glnfs*34)	frameshift_variant	2.77
03-015	ASXL1	NM_015338.5:c.1249C>T	NP_056153.2:p.(Arg417*)	stop_gained	4.51
03-015	ASXL1	NM_015338.5:c.2485C>T	NP_056153.2:p.(Gln829*)	stop_gained	16.20
03-020	TET2	NM_001127208.2:c.3734A>G	NP_001120680.1:p.(Tyr1245Cys)	missense_variant	8.45
03-020	TET2	NM_001127208.2:c.4056del	NP_001120680.1:p.(Glu1352Aspfs*11)	frameshift_variant	10.47
03-025	DNMT3A	NM_022552.4:c.912del	NP_072046.2:p.(Trp305Glyfs*11)	frameshift_variant	11.37
03-031	TP53	NM_000546.5:c.733G>C	NP_000537.3:p.(Gly245Arg)	missense_variant	3.85
03-031	EZH2	NM_004456.4:c.2007C>G	NP_004447.2:p.(Ser669Arg)	missense_variant	30.84
03-032	DNMT3A	NM_022552.4:c.2207G>A	NP_072046.2:p.(Arg736His)	missense_variant	2.73
03-032	PPM1D	NM_003620.3:c.1568C>T	NP_003611.1:p.(Ala523Val)	missense_variant	11.68
03-040	TET2	NM_001127208.2:c.1995_1998del	NP_001120680.1:p.(Asp666Ilefs*33)	frameshift_variant	4.28
03-040	DNMT3A	NM_022552.4:c.2206C>T	NP_072046.2:p.(Arg736Cys)	missense_variant	6.34
03-045	ASXL1	NM_015338.5:c.2177del	NP_056153.2:p.(Lys726Argfs*18)	frameshift_variant	2.77
03-049	DNMT3A	NM_022552.4:c.1096C>A	NP_072046.2:p.(Arg366Ser)	frameshift_variant	6.72
03-054	JAK2	NM_004972.3:c.1849G>T	NP_004963.1:p.(Val617Phe)	missense_variant	1.93
03-054	DNMT3A	NM_022552.4:c.820_821insTT	NP_072046.2:p.(Ala274Valfs*43)	frameshift_variant	2.20
03-060	DNMT3A	NM_022552.4:c.2183del	NP_072046.2:p.(Gly728Alafs*51)	frameshift_variant	3.27
03-060	DNMT3A	NM_022552.4:c.1717C>T	NP_072046.2:p.(Gln573*)	stop_gained	6.97
03-064	TET2	NM_001127208.2:c.2083dup	NP_001120680.1:p.(Met695Asnfs*17)	frameshift_variant	6.80
03-073	TET2	NM_001127208.2:c.4726_4733del	NP_001120680.1:p.(Val1576Leufs*35)	frameshift_variant	4.70
03-077	JAK2	NM_004972.3:c.1849G>T	NP_004963.1:p.(Val617Phe)	missense_variant	24.22

03-081	DNMT3A	NM_022552.4:c.2253C>G	NP_072046.2:p.(Phe751Leu)	missense_variant	13.98
03-084	TET2	NM_001127208.2:c.5602C>T	NP_001120680.1:p.(His1868Tyr)	missense_variant	1.75
03-090	DNMT3A	NM_022552.4:c.2577dup	NP_072046.2:p.(Trp860Metfs*4)	frameshift_variant	3.52
03-090	TET2	NM_001127208.2:c.840dup	NP_001120680.1:p.(Asn281*)	frameshift_variant	3.98
03-090	DNMT3A	NM_022552.4:c.2206C>T	NP_072046.2:p.(Arg736Cys)	missense_variant	5.52
03-091	TET2	NM_001127208.2:c.4997_5010del	NP_001120680.1:p.(Pro1666Glnfs*16)	frameshift_variant	6.58
03-093	DNMT3A	NM_022552.4:c.2644C>T	NP_072046.2:p.(Arg882Cys)	missense_variant	7.39
03-096	DNMT3A	NM_022552.4:c.1554+1del	p.?	splice_donor_variant	2.20
03-096	TET2	NM_001127208.2:c.2474del	NP_001120680.1:p.(Ser825*)	frameshift_variant	3.26
03-100	TET2	NM_001127208.2:c.5703_5704del	NP_001120680.1:p.(Phe1901Leufs*4)	frameshift_variant	2.41
03-100	DNMT3A	NM_022552.4:c.1883del	NP_072046.2:p.(Ala628Valfs*23)	frameshift_variant	2.96
03-101	DNMT3A	NM_022552.4:c.1583_1603dup	NP_072046.2:p.(Tyr528_Gln534dup)	inframe_insertion	2.51
03-102	DNMT3A	NM_022552.4:c.2676_2677del	NP_072046.2:p.(Trp893Glufs*27)	frameshift_variant	2.07
03-112	DNMT3A	NM_022552.4:c.2193_2195del	NP_072046.2:p.(Phe732del)	inframe_deletion	2.66
03-127	DNMT3A	NM_022552.4:c.2259del	NP_072046.2:p.(Trp753Cysfs*26)	frameshift_variant	2.48
03-127	DNMT3A	NM_022552.4:c.2409-1G>A	p.?	splice_acceptor_variant	3.63
03-129	DNMT3A	NM_022552.4:c.880G>T	NP_072046.2:p.(Glu294*)	stop_gained	8.69
03-130	TET2	NM_001127208.2:c.3881A>G	NP_001120680.1:p.(Tyr1294Cys)	missense_variant	15.18
03-131	TET2	NM_001127208.2:c.3680T>G	NP_001120680.1:p.(Val1227Gly)	missense_variant	3.54
03-135	DNMT3A	NM_022552.4:c.892G>T	NP_072046.2:p.(Gly298Trp)	missense_variant	8.60
03-140	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	4.88
03-143	DNMT3A	NM_022552.4:c.2206C>T	NP_072046.2:p.(Arg736Cys)	missense_variant	1.96
06-001	MPL	NM_005373.2:c.1487C>T	NP_005364.1:p.(Thr496Ile)	missense_variant	2.56
06-004	TET2	NM_001127208.2:c.4133G>A	NP_001120680.1:p.(Cys1378Tyr)	missense_variant	5.00
06-006	DNMT3A	NM_022552.4:c.1630_1631insT	NP_072046.2:p.(Arg544Leufs*2)	frameshift_variant	3.41
06-006	DNMT3A	NM_022552.4:c.886G>A	NP_072046.2:p.(Val296Met)	missense_variant	3.64
06-007	DNMT3A	NM_022552.4:c.2644C>T	NP_072046.2:p.(Arg882Cys)	missense_variant	1.33
06-008	DNMT3A	NM_022552.4:c.939G>A	NP_072046.2:p.(Trp313*)	stop_gained	2.38
06-016	DNMT3A	NM_022552.4:c.1816C>T	NP_072046.2:p.(Gln606*)	stop_gained	20.96
06-018	DNMT3A	NM_022552.4:c.2387del	NP_072046.2:p.(Gly796Valfs*6)	frameshift_variant	5.83
06-021	DNMT3A	NM_022552.4:c.942G>A	NP_072046.2:p.(Trp314*)	stop_gained	4.33
06-026	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	1.12

06-046	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	1.50
06-050	SF3B1	NM_012433.2:c.2098A>G	NP_036565.2:p.(Lys700Glu)	missense_variant	7.02
06-055	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	1.11
06-062	DNMT3A	NM_022552.4:c.2165del	NP_072046.2:p.(Gly722Alafs*57)	frameshift_variant	8.03
06-067	ASXL1	NM_015338.5:c.4127dup	NP_056153.2:p.(Pro1377Serfs*3)	frameshift_variant	5.30
06-072	PPM1D	NM_003620.3:c.1642A>G	NP_003611.1:p.(Lys548Glu)	missense_variant	2.39
06-072	DNMT3A	NM_022552.4:c.1015-1G>A	p.?	splice_acceptor_variant	7.63
10-002	PPM1D	NM_003620.3:c.1423del	NP_003611.1:p.(Glu475Lysfs*8)	frameshift_variant	4.22
10-003	TET2	NM_001127208.2:c.2079del	NP_001120680.1:p.(Lys693Asnfs*7)	frameshift_variant	3.01
10-006	DNMT3A	NM_022552.4:c.990G>A	NP_072046.2:p.(Trp330*)	stop_gained	3.11
10-006	DNMT3A	NM_022552.4:c.1066C>T	NP_072046.2:p.(Gln356*)	stop_gained	11.79
10-011	DNMT3A	NM_022552.4:c.2578T>C	NP_072046.2:p.(Trp860Arg)	missense_variant	2.56
10-013	DNMT3A	NM_022552.4:c.990G>A	NP_072046.2:p.(Trp330*)	stop_gained	1.38
10-016	DNMT3A	NM_022552.4:c.1652_1657delinsC	NP_072046.2:p.(Asn551Thrfs*25)	frameshift_variant	7.09
10-024	DNMT3A	NM_022552.4:c.2355_2356insCT	NP_072046.2:p.(Ser786Leufs*17)	frameshift_variant	9.73
10-031	DNMT3A	NM_022552.4:c.2206C>T	NP_072046.2:p.(Arg736Cys)	missense_variant	1.71
10-034	SF3B1	NM_012433.2:c.1984C>T	NP_036565.2:p.(His662Tyr)	missense_variant	1.47
10-034	DNMT3A	NM_022552.4:c.2193C>G	NP_072046.2:p.(Phe731Leu)	missense_variant	2.02
10-034	TET2	NM_001127208.2:c.244dup	NP_001120680.1:p.(Ser82Lysfs*2)	frameshift_variant	2.73
10-036	DNMT3A	NM_022552.4:c.2644C>T	NP_072046.2:p.(Arg882Cys)	missense_variant	2.15
10-036	ASXL1	NM_015338.5:c.1900_1922del	NP_056153.2:p.(Glu635Argfs*15)	frameshift_variant	12.64
10-063	DNMT3A	NM_022552.4:c.1656del	NP_072046.2:p.(Asn552Lysfs*99)	frameshift_variant	3.33
10-063	DNMT3A	NM_022552.4:c.958C>T	NP_072046.2:p.(Arg320*)	stop_gained	10.89
10-076	TET2	NM_001127208.2:c.5507_5508del	NP_001120680.1:p.(Val1836Glyfs*9)	frameshift_variant	2.28
12-006	ASXL1	NM_015338.5:c.2035G>T	NP_056153.2:p.(Gly679*)	stop_gained	7.05
12-008	DNMT3A	NM_022552.4:c.1823del	NP_072046.2:p.(Phe608Serfs*43)	frameshift_variant	3.51
18-013	TP53	NM_000546.5:c.772G>A	NP_000537.3:p.(Glu258Lys)	missense_variant	8.38
18-013	DNMT3A	NM_022552.4:c.846dup	NP_072046.2:p.(Glu283Argfs*41)	frameshift_variant	12.95
18-014	SF3B1	NM_012433.2:c.2098A>G	NP_036565.2:p.(Lys700Glu)	missense_variant	3.65
18-014	DNMT3A	NM_022552.4:c.2479-1G>A	p.?	splice_acceptor_variant	7.11
18-019	DNMT3A	NM_022552.4:c.2193_2195del	NP_072046.2:p.(Phe732del)	inframe_deletion	6.37
18-055	ASXL1	NM_015338.5:c.1900_1922del	NP_056153.2:p.(Glu635Argfs*15)	frameshift_variant	20.31

20-003	ASXL1	NM_015338.5:c.3514del	NP_056153.2:p.(Ala1172Leufs*2)	frameshift_variant	1.46
20-003	DNMT3A	NM_022552.4:c.2311C>T	NP_072046.2:p.(Arg771*)	stop_gained	2.73
20-006	ASXL1	NM_015338.5:c.2117del	NP_056153.2:p.(His706Leufs*19)	frameshift_variant	5.03
20-006	TET2	NM_001127208.2:c.822del	NP_001120680.1:p.(Asn275Ilefs*18)	frameshift_variant	5.34
20-006	TET2	NM_001127208.2:c.4133G>A	NP_001120680.1:p.(Cys1378Tyr)	missense_variant	13.46
20-007	STAT3	NM_139276.2:c.1999G>T	NP_644805.1:p.(Val667Leu)	missense_variant	4.61
20-008	TET2	NM_001127208.2:c.4567C>T	NP_001120680.1:p.(Gln1523*)	stop_gained	4.68
20-012	TET2	NM_001127208.2:c.4399dup	NP_001120680.1:p.(Arg1467Lysfs*11)	frameshift_variant	2.93
20-012	DNMT3A	NM_022552.4:c.2207G>A	NP_072046.2:p.(Arg736His)	missense_variant	3.38
20-018	U2AF1	NM_006758.2:c.470A>C	NP_006749.1:p.(Gln157Pro)	missense_variant	3.78
20-025	ASXL1	NM_015338.5:c.2324del	NP_056153.2:p.(Leu775*)	frameshift_variant	13.53
20-029	TET2	NM_001127208.2:c.2759del	NP_001120680.1:p.(Leu920*)	frameshift_variant	2.18
21-001	TET2	NM_001127208.2:c.3733_3737del	NP_001120680.1:p.(Tyr1245Glyfs*21)	frameshift_variant	13.14
21-004	DNMT3A	NM_022552.4:c.1851+1G>A	p.?	splice_donor_variant	2.21
21-009	DNMT3A	NM_022552.4:c.2106T>A	NP_072046.2:p.(Asp702Glu)	missense_variant	3.13
21-017	ASXL1	NM_015338.5:c.1247_1248del	NP_056153.2:p.(Leu416Profs*21)	frameshift_variant	11.44
27-001	DNMT3A	NM_022552.4:c.855+1G>A	p.?	splice_donor_variant	1.31
27-002	ASXL1	NM_015338.5:c.2278C>T	NP_056153.2:p.(Gln760*)	stop_gained	16.69
27-003	STAG2	NM_006603.4:c.192_193insGA	NP_006594.3:p.(Ser65Aspfs*7)	frameshift_variant	18.38
27-008	ASXL1	NM_015338.5:c.2535dup	NP_056153.2:p.(Ser846Glnfs*5)	frameshift_variant	7.13
27-008	SETBP1	NM_015559.2:c.2602G>A	NP_056374.2:p.(Asp868Asn)	missense_variant	16.00
27-008	U2AF1	NM_006758.2:c.470A>C	NP_006749.1:p.(Gln157Pro)	missense_variant	41.75
27-008	TP53	NM_000546.5:c.455C>T	NP_000537.3:p.(Pro152Leu)	missense_variant	42.75
27-015	ASXL1	NM_015338.5:c.2143A>T	NP_056153.2:p.(Arg715*)	stop_gained	16.25
27-016	TET2	NM_001127208.2:c.1669C>T	NP_001120680.1:p.(Gln557*)	stop_gained	2.71
27-019	TP53	NM_000546.5:c.542G>A	NP_000537.3:p.(Arg181His)	missense_variant	2.47
30-001	TET2	NM_001127208.2:c.3311_3312del	NP_001120680.1:p.(Phe1104Tyrfs*25)	frameshift_variant	14.14
30-003	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	2.15
30-009	JAK2	NM_004972.3:c.1849G>T	NP_004963.1:p.(Val617Phe)	missense_variant	4.73
30-009	TET2	NM_001127208.2:c.2626C>T	NP_001120680.1:p.(Gln876*)	stop_gained	5.01
30-014	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	45.24
30-016	DNMT3A	NM_022552.4:c.1809_1810del	NP_072046.2:p.(Arg604Alafs*7)	frameshift_variant	1.95

30-017	U2AF1	NM_006758.2:c.470A>C	NP_006749.1:p.(Gln157Pro)	missense_variant	6.56
30-019	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	16.15
30-021	TET2	NM_001127208.2:c.4714C>T	NP_001120680.1:p.(Arg1572Trp)	missense_variant	5.37
30-023	DNMT3A	NM_022552.4:c.2640G>T	NP_072046.2:p.(Met880Ile)	missense_variant	1.96
30-025	DNMT3A	NM_022552.4:c.2645G>A	NP_072046.2:p.(Arg882His)	missense_variant	2.54
30-027	TP53	NM_000546.5:c.659A>G	NP_000537.3:p.(Tyr220Cys)	missense_variant	5.86
30-028	DNMT3A	NM_022552.4:c.855+1G>A	p.?	splice_donor_variant	1.71
30-028	TET2	NM_001127208.2:c.3781C>T	NP_001120680.1:p.(Arg1261Cys)	missense_variant	8.57
30-028	ASXL1	NM_015338.5:c.1249C>T	NP_056153.2:p.(Arg417*)	stop_gained	35.82

**Supplementary Table S5. Sensitivity analysis of the association between HIV infection and the presence of having  $\geq 1$  CH mutation**

**Supplementary Table S5.A. Mutations with variant allele fraction>2% only<sup>1</sup>:** 88 (19.7%) of 446 participants (200 HIV positive, 226 HIV negative) had  $\geq 1$  CH mutation with VAF>2%

	No CH mutation N=358	$\geq 1$ CH mutation N=88	OR (95% CI) Unadjusted	p-value unadjusted	OR (95% CI) adjusted for age, gender, smoking and sexual orientation	p-value adjusted for age, gender, smoking and sexual orientation
<b>HIV status</b>						
HIV negative	195 (54.5)	31 (35.2)		Ref		
HIV positive	163 (45.5)	57 (64.8)	2.20 (1.36-3.57)	0.001	2.47 (1.48-4.11)	<0.001
Missing	0	0				
<b>Age</b>						
Median age (IQR)	63 (59-68)	66 (61-71)	1.07 (1.04-1.12)	<0.001	1.08 (1.04-1.13)	<0.001
Missing	0	0				
<b>Gender</b>						
Female	13 (3.6)	4 (4.6)		Ref		
Male	345 (96.4)	84 (95.5)	0.79 (0.25-2.49)	0.69	0.53 (0.11-2.49)	0.42
Missing	0	0				
<b>Sexual orientation</b>						

Other	35 (9.8)	8 (9.1)	Ref			
MSM	313 (87.4)	77 (87.5)	1.08 (0.48-2.41)	0.86	1.30 (0.45-3.77)	0.63
Missing	10 (2.8)	3 (3.4)				
<b>Smoking</b>						
Never smoked	162 (45.3)	33 (37.5)	Ref			
Ever smoked	154 (43.0)	46 (52.3)	1.47 (0.89-2.41)	0.13	1.39 (0.83-2.33)	0.21
Missing	42 (11.7)	9 (10.2)				

---

<sup>1</sup>In this model, if a participant had multiple mutations, they were classified as having any CH mutation if any of the mutations had a VAF >2.

**Supplementary Table S5.B. Mutations in DNMT3A, TET2 and ASXL1 only**<sup>1</sup>: 85 (19.1%) of 446 participants (200 HIV positive, 226 HIV negative) had  $\geq 1$  CH mutation in DNMT3A, TET2 or ASXL1

	No CH mutation (N=361)	$\geq 1$ CH mutation (N=85)	OR (95% CI) Unadjusted	p-value unadjusted	OR (95% CI) adjusted for age, gender, smoking and sexual orientation	p-value adjusted for age, gender, smoking and sexual orientation
<b>HIV status</b>						
HIV negative	194 (53.7)	32 (37.7)		Ref		
HIV positive	167 (46.3)	53 (62.4)	1.92 (1.18-3.13)	0.008	2.08 (1.26-3.46)	0.004
Missing	0	0				
<b>Age</b>						
Median age (IQR)	63 (59-68)	66 (61-70)	1.07 (1.03-1.11)	<0.001	1.07 (1.03-1.12)	<0.001
Missing	0	0				
<b>Gender</b>						
Female	13 (3.6)	4 (4.7)		Ref		
Male	348 (96.4)	81 (95.3)	0.76 (0.24-2.38)	0.63	0.64 (0.14-2.95)	0.57
Missing	0	0				
<b>Sexual orientation</b>						
Other	34 (9.4)	9 (10.6)		Ref		
MSM	315 (87.3)	75 (88.2)	0.90 (0.41-1.96)	0.79	1.02 (0.37-2.80)	0.97

Missing	12 (3.3)	1 (1.2)				
Smoking						
Never smoked	163 (45.2)	32 (37.7)	Ref			
Ever smoked	156 (43.2)	44 (51.8)	1.44 (0.87-2.38)	0.16	1.39 (0.82-2.33)	0.22
Missing	42 (11.6)	9 (10.6)				

---

<sup>1</sup>In this model, if a participant had multiple mutations, they were classified as having any CH mutation if any of the mutations were in DNMT3A, TET2 or ASXL1.

**Supplementary Table S5.C. Men only:** N=95 (22.1%) of 429 male participants (216 HIV positive, 213 HIV negative) had  $\geq 1$  CH mutation

	No CH mutation (N=334)	$\geq 1$ CH mutation (N=95)	OR (95% CI) Unadjusted	p-value unadjusted	OR (95% CI) adjusted for age, smoking and sexual orientation	p-value adjusted for age, smoking and sexual orientation
<b>HIV status</b>						
HIV negative	117 (53.0)	36 (37.9)	Ref			
HIV positive	157 (47.0)	59 (62.1)	1.85 (1.16-2.95)	0.01	2.04 (1.26-3.32)	0.004
Missing	0	0				
<b>Age</b>						
Median age (IQR)	63 (59-68)	66 (61-71)	1.08 (1.04-1.12)	<0.001	1.08 (1.04-1.13)	<0.001
Missing	0	0				
<b>Sexual orientation</b>						
Other	21 (6.3)	6 (6.3)	Ref			
MSM	304 (91.0)	86 (90.5)	0.99 (0.39-2.53)	0.98	0.99 (0.38-2.58)	0.98
Missing	9 (2.7)	3 (3.2)				
<b>Smoking</b>						
Never smoked	152 (45.5)	37 (39.0)	Ref			
Ever smoked	143 (42.8)	47 (49.5)	1.35 (0.83-2.20)	0.23	1.27 (0.77-2.10)	0.36
Missing	39 (11.7)	11 (11.6)				

**Supplementary Table S5.D. MSM only:** 86 (22.1%) of 390 MSM participants (201 HIV positive, 189 HIV negative) had  $\geq 1$  CH mutation

	No CH mutation (N=304)	$\geq 1$ CH mutation (N=86)	OR (95% CI) Unadjusted	p-value unadjusted	OR (95% CI) adjusted for age and smoking	p-value adjusted for age and smoking
<b>HIV status</b>						
HIV negative	157 (51.6)	32 (37.2)		Ref		
HIV positive	147 (48.4)	54 (62.8)	1.80 (1.10-2.95)	0.02	1.98 (1.19-3.31)	0.009
Missing	0	0				
<b>Age</b>						
Median age (IQR)	63 (58-67)	66 (61-71)	1.08 (1.03-1.12)	<0.001	1.08 (1.04-1.13)	<0.001
Missing	0	0				
<b>Smoking</b>						
Never smoked	141 (46.4)	34 (39.5)		Ref		
Ever smoked	129 (42.4)	41 (47.7)	1.32 (0.79-2.20)	0.29	1.24 (0.73-2.10)	0.43
Missing	34 (11.2)	11 (12.8)				

**Supplementary Table S6. Univariate analysis of risk factors for having  $\geq$  one CH mutation among HIV positive participants (N=220)**

	No CH Mutation N=159	Any CH Mutation N=61	Univariate	Univar p-value
			OR (95% CI)	
Median age (IQR)	62 (59-67)	66 (61-71)	1.11 (1.05-1.17)	<0.001
Missing	0	0		
Gender				
Female	2 (1.3)	2 (3.3)	Ref	
Male	157 (98.7)	59 (96.7)	0.38 (0.05-2.73)	0.33
Missing	0	0		
Sexual orientation				
Other	9 (5.7)	6 (9.8)	Ref	
MSM	147 (92.5)	54 (88.5)	0.55 (0.19-1.62)	0.28
Missing	3 (1.9)	1 (1.6)		
Years since HIV diagnosis,				
Median (IQR)*	23 (14-30)	26 (16-31)	1.01 (0.98-1.04)	0.69
<10	14 (8.8)	7 (11.5)	Ref	
10-19	48 (30.2)	16 (26.2)	0.67 (0.23-1.94)	0.46
20-29	47 (29.6)	18 (29.5)	0.77 (0.27-2.21)	0.62
$\geq$ 30	46 (28.9)	20 (32.8)	0.87 (0.31-2.48)	0.79
Missing	4 (2.5)	0		

<20	62 (39.0)	23 (37.7)	Ref	
≥20	93 (58.5)	38 (62.3)	1.10 (0.60-2.03)	0.76
Missing	4 (2.5)	0		
CD4 nadir, Median (IQR)	242 (133-372)	271 (170-400)	1.00 (0.99-1.00)	0.26
≥500	20 (12.6)	8 (13.1)	Ref	
200-499	80 (50.3)	34 (55.7)	1.06 (0.43-2.65)	0.90
<200	56 (35.2)	19 (31.2)	0.85 (0.32-2.24)	0.74
Missing	3 (1.9)	0		
≥200	100 (62.9)	42 (68.9)	Ref	
<200	56 (35.2)	19 (31.2)	0.81 (0.43-1.52)	0.51
Missing	3 (1.9)	0		
Current CD4 count				
Median (IQR)	650 (483-865)	626 (444-783)	1.00 (0.99-1.00)	0.62
≥500	115 (72.3)	38 (62.3)	Ref	
350-499	24 (15.1)	15 (24.6)	1.89 (0.90-3.97)	0.09
<350	18 (11.3)	8 (13.1)	1.35 (0.54-3.34)	0.52
Missing	2 (1.3)	0		
≥500	115 (72.3)	38 (62.3)	Ref	
<500	42 (26.4)	23 (37.7)	1.66 (0.89-3.10)	0.11
Missing	2 (1.3)	0		
Current HIV viral load				

<40	152 (95.6)	58 (95.1)	Ref	
≥40	7 (4.4)	3 (4.9)	1.12 (0.28-4.49)	0.87
Missing	0	0		
<hr/>				
When started ART	129 (81.1)	42 (68.9)		
Modern HAART (since 2006)	62 (39.0)	21 (34.4)	Ref	
Early HAART (1996-2005)	67 (42.1)	21 (34.4)	0.93 (0.46-1.86)	0.83
Pre-HAART (before 1996)	26 (16.4)	14 (23.0)	1.59 (0.70-3.60)	0.27
Missing	4 (2.5)	5 (8.2)		
<hr/>				
Years from diagnosis to start of				
ART, Median (IQR)	5 (1-11)	4.5 (1-10)	0.99 (0.94-1.04)	0.66
<hr/>				
Within 1 year	36 (22.6)	12 (19.7)	Ref	
1-4 years	35 (22.0)	16 (26.2)	1.37 (0.57-3.31)	0.48
5-9 years	32 (20.1)	13 (21.3)	1.22 (0.49-3.05)	0.67
≥10 years	48 (30.2)	15 (24.6)	0.94 (0.29-2.25)	0.88
Missing	8 (5.0)	5 (8.2)		
<hr/>				
Years of HIV therapy, Median (IQR)	17 (10-21)	19 (9-23)	1.01 (0.97-1.06)	0.51
<hr/>				
<10	38 (23.9)	15 (25.6)	Ref	
10-19	62 (39.0)	15 (24.6)	0.61 (0.27-1.39)	0.24
≥20	53 (33.3)	24 (39.3)	1.20 (0.56-2.56)	0.64
Missing	4 (2.5)	5 (8.2)		
<hr/>				
<20	100 (62.9)	30 (49.2)	Ref	

$\geq 20$	55 (34.6)	26 (42.6)	1.58 (0.85-2.93)	0.15
Missing	4 (2.5)	5 (8.2)		
<hr/>				
Proportion of time since HIV				
diagnosis that participant was				
taking ART**				
$>75\%$	79 (49.7)	29 (47.5)	Ref	
$\leq 75\%$	72 (45.3)	27 (44.3)	1.02 (0.55-1.89)	0.95
Missing	8 (5.0)	5 (8.2)		
<hr/>				
Ever took stavudine				
No	103 (64.8)	35 (57.4)	Ref	
Yes	54 (34.0)	23 (37.7)	1.25 (0.67-2.33)	0.48
Missing	2 (1.3)	3 (4.9)		
<hr/>				
Ever took zidovudine				
No	90 (56.6)	34 (55.7)	Ref	
Yes	67 (42.1)	24 (39.3)	3.97 (0.64-24.81)	0.86
Missing	2 (1.3)	3 (4.9)		
<hr/>				
Ever took stavudine or				
zidovudine				
No	74 (46.5)	26 (42.6)	Ref	
Yes	83 (52.2)	32 (52.5)	1.10 (0.60-2.01)	0.76
Missing	2 (1.3)	3 (4.9)		
<hr/>				
Current or prior HBV or HCV				
infection				
No	132 (83.0)	51 (83.6)	Ref	
Yes	27 (17.0)	10 (16.4)	0.96 (0.43-2.12)	0.92


Missing	0	0
---------	---	---

---

\*number of years from year of diagnosis to year of enrolment


\*\*years on ART / years since diagnosis

**Supplementary Figure S1: Variant allele fraction by duration of HIV, among HIV positive participants<sup>1</sup>**



<sup>1</sup>Mean average variant allele fraction was calculated if there was more than one CH mutation present

## Supplementary Figure S2. Box plots of the distribution of blood cell characteristics and inflammatory markers.



Overall p-values (figure inset) were generated using the Kruskal-Wallis test. P-values across specific groups (brackets) were generated using post-hoc pairwise two-sided multiple comparison analysis using the Dwass, Steel, Critchlow-Fligner Method.

Panel A. White cell count by HIV status and presence of 0, 1 and >1 CH mutation

Panel B. Haemoglobin by HIV status and presence of 0, 1 and >1 CH mutation. Haemoglobin was assessed among male participants only due to physiologic differences in haemoglobin across gender, and low numbers of women in our study.

Panel C. Cystatin C\* by HIV status and presence of 0, 1 and >1 CH mutation

Panel D. Interleukin-6\* by *IL6R p. Asp358Ala* status and HIV status

\*Outliers have been removed for box plot presentation only; p-values were calculated including outliers. Outliers were defined as values greater than 1.5 times the IQR above the third quartile.

## **References**

- 1.Doig KD, Fellowes A, Bell AH, et al. PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories. *Genome medicine* 2017;9:38.
- 2.Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in medicine : official journal of the American College of Medical Genetics* 2015;17:405-24.